Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136663 | 0.87 | NPSR1 (0.49) | CYP17A1CYP19A1NPSR1THRBMEN1 | |
| SCHEMBL9987662 | 0.86 | THRB (0.41) | CYP17A1CYP19A1NPSR1THRBGAA | |
| SCHEMBL5568146 | 0.81 | ALDH1A1 (0.44) | CYP17A1CYP19A1NPSR1MEN1MAPK1 | |
| SCHEMBL2338250 | 0.81 | POLB (0.42) | CYP17A1CYP19A1NPSR1THRBMEN1 | |
| SCHEMBL133074 | 0.81 | ALDH1A1 (0.49) | CYP17A1CYP19A1NPSR1HSD11B1L3MBTL1 | |
| SCHEMBL9987665 | 0.80 | ALDH1A1 (0.46) | THRBMEN1MAPK1KMT2AGAA | |
| SCHEMBL131064 | 0.79 | CYP17A1 (0.55) | CYP17A1CYP19A1NPSR1MEN1MAPK1 | |
| SCHEMBL9988376 | 0.79 | CYP17A1 (0.37) | CYP17A1CYP19A1NPSR1MEN1MAPK1 | |
| SCHEMBL15436194 | 0.78 | CYP17A1 (0.40) | CYP17A1CYP19A1NPSR1THRBMEN1 | |
| SCHEMBL5410234 | 0.76 | NPSR1 (0.40) | CYP17A1CYP19A1NPSR1THRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598292-B2 | Adamantane derivative, method for producing same, polymer using same as starting material, and resin composition | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| US-20110319584-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING SAME, POLYMER USING SAME AS STARTING MATERIAL, AND RESIN COMPOSITION | MITSUBISHI GAS CHEMICAL COMPANY, INC (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319584-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING SAME, POLYMER USING SAME AS STARTING MATERIAL, AND RESIN COMPOSITION | EEF1A1, ADGRF1, ERCC4 | CYP17A1 2378/4885CYP19A1 2970/4885NPSR1 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.